Medicus Pharma advances Teverelix Phase 2 study after FDA feedback, IRB approval
Medicus Pharma (NASDAQ:MDCX) said it received US FDA feedback and central IRB approval for an optimized Phase 2 study of Teverelix (ANT-2111-02) in men after a first acute urinary retention episode. The trial will enroll about 126 patients in the US and Europe, down from ~390, and evaluate Teverelix DP on prostate volume and urinary function. FDA comments were operational, and the IRB approval runs for one year.
How this was made
The 30-second read
Why it matters
FDA feedback and central IRB approval for ANT-2111-02 are meaningful execution milestones. The redesign reduces planned enrollment from ~390 to ~126 while keeping the scientific rationale and primary endpoint unchanged, which can improve efficiency and decision-grade evidence generation.
Market read
A concrete regulatory milestone plus a quantified enrollment reduction is likely to support MDCX sentiment and can influence expectations for trial start-up and operational risk.
What to watch
The article notes operational FDA comments and one-year IRB approval, but does not quantify expected start date, interim readout timing, or any remaining regulatory hurdles at local sites.
Background
Medicus is advancing Teverelix (a long-acting GnRH antagonist) in men after a first episode of acute urinary retention; the Phase 2 study was redesigned after FDA feedback.
Ticker impact
Medicus Pharma received US FDA feedback and central IRB approval for a redesigned Teverelix Phase 2 study, cutting enrollment to ~126 patients.
Likely supportive for MDCX, with follow-through dependent on site activation and enrollment start.
The article discloses a concrete regulatory milestone (FDA feedback plus central IRB approval) and quantifies the enrollment reduction, which can de-risk operational execution versus the prior plan.
Market effects
Positive read-through for urology-focused biotech trial execution, but impact is company-specific given the single-issuer milestone.
No clear regional market linkage beyond US-listed small-cap biotech sentiment.
Trial enrollment spans US and Europe, but the disclosed milestone is US FDA and central IRB driven.
Counterpoint
Protocol approval does not guarantee faster enrollment; local site authorizations and start-up timelines can still slip.
Key entities
- companyMedicus Pharma
NASDAQ-listed company advancing Teverelix Phase 2 after receiving FDA feedback and central IRB approval.
- drugTeverelix DP
Long-acting gonadotropin-releasing hormone antagonist evaluated in the redesigned Phase 2 trial.
- clinical_trialANT-2111-02
Optimized Phase 2 study protocol for Teverelix in men following first episode acute urinary retention.
- regulatory_bodyAdvarra
Central IRB that approved the protocol with modifications and a one-year approval period.
- regulatorUS FDA
Provided seven comments on protocol implementation, safety monitoring, and clarifications.
